PT-141 vs MK-677
A comprehensive, data-driven comparison of PT-141 (Bremelanotide) and MK-677 (Ibutamoren). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | PT-141 Bremelanotide, Vyleesi | MK-677 Ibutamoren, Nutrobal |
|---|---|---|
| FDA Status | FDA Approved | Phase 2 |
| Category | Sexual Health | Growth Hormone |
| Primary Use | Hypoactive sexual desire disorder (HSDD) in women | Growth hormone optimization and muscle growth |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $800 - $1,200/mo | $50 - $100/mo |
| Administration | Subcutaneous injection | Oral |
| Typical Dose | 1.75mg as needed, at least 45 min before activity | 10-25mg daily |
| Frequency | As needed | Daily |
| Mechanism | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal | Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Moderate |
| Clinical Trial Phase | Approved | Phase 2 |
Key Differences
- 1PT-141 is FDA-approved, while MK-677 is currently phase 2.
- 2MK-677 is generally more affordable ($50 - $100/mo) compared to PT-141 ($800 - $1,200/mo).
- 3PT-141 is administered via subcutaneous injection, while MK-677 uses oral.
- 4PT-141 is dosed as needed, while MK-677 is daily.
- 5PT-141 has high-quality evidence, while MK-677 has moderate-quality evidence.
- 6They belong to different categories: PT-141 (Sexual Health) vs MK-677 (Growth Hormone).
Which Is Better For...
PT-141
Those seeking an FDA-approved treatment with established safety data
MK-677
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
PT-141
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
| MK-677 | $50 - $100/mo | Phase 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.
PT-141 typically costs $800 - $1,200/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
PT-141 is FDA-approved. MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideMK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing...
View Full MK-677 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between PT-141 and MK-677 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.